Mucinous carcinoma of the breast (type B, ER+/PR-/Her2 3+) with chemoresistance (Herceptin)


Figure 1. Her2 overexpression in the tumor cells (after neoadjuvant chemoterapy + Herceptin)	Figure 2. Her2 overexpression in the tumor cells (after neoadjuvant chemoterapy + Herceptin)

Figure 3. Some tumor cells showed 2+ Her2 positivity.